Introduction {#s1}
============

The pancreas is an essential dual-functioning organ that contains an exocrine and endocrine compartment. The exocrine pancreas represents the majority of the pancreatic tissue and contains acinar cells that secrete digestive enzymes and the ductal cells through which the enzymes are transported into the duodenum. The endocrine pancreas only represents 1--2% of the organ, but is comprised of hormone-producing islet cells that are critical for the maintenance of glucose homeostasis. Interestingly, although these two compartments have highly disparate functions, they arise from a common multipotent progenitor population that gradually forms spatially and molecularly distinct progenitor subpopulations during development ([@bib6]; [@bib28]; [@bib30]; [@bib47]). A bi-potent duct/endocrine progenitor population is then derived from the multipotent progenitor population and subsequently differentiates into a highly restricted endocrine progenitor population that produces all islet cell types, including the functionally important insulin-producing β cell lineage.

The progressive restriction of progenitor-cell lineage potential to ultimately give rise to pancreatic islet cells is believed to be regulated by the sequential expression of several essential transcription factors. The multipotent progenitor population is defined by the expression of Pancreatic and duodenal homeobox 1 (Pdx1) and Pancreas transcription factor 1a (Ptf1a), transcriptional regulators that are essential for pancreatic formation; deletion of *Pdx1* or *Ptf1a* leads to pancreatic agenesis ([@bib6]; [@bib14]; [@bib19]; [@bib22]; [@bib28]). A subset of cells from the Pdx1^+^ Ptf1a^+^ multipotent progenitors gradually become restricted to the endocrine lineage with the expression of Neurogenin 3 (Neurog3), which delineates the endocrine progenitor population. Neurog3 is essential for the formation of all six embryonic pancreatic endocrine cell types: the insulin-producing β cells, glucagon-producing α cells, somatostatin-producing δ cells, pancreatic polypeptide-producing PP cells, gastrin-producing G cells, and ghrelin-producing ε cells ([@bib13]; [@bib15]; [@bib16]; [@bib38]; [@bib41]). Mice lacking *Neurog3* almost completely fail to form these endocrine lineages ([@bib13]; [@bib16]; [@bib41]).

Although it is well-established that β cells are derived from the Neurog3^+^ progenitor lineage, there is still some uncertainty about when and where the β cell lineage is specified during pancreas development. β cell fate may be influenced early within the Pdx1^+^ pancreatic progenitor to specify unipotent populations of Neurog3^+^ endocrine progenitor cells ([@bib9]) or it may be occurring within the Neurog3^+^ endocrine progenitor lineage after induction of *Neurog3*. Interestingly, [@bib18] demonstrated that pancreatic progenitor cells transition through distinct competence windows in response to *Neurog3* induction for each endocrine cell fate, with β cell competence being acquired during a window of development between embryonic day (E)10.5 and E16 ([@bib18]).

Many of the transcription factors that are essential for β cell specification have been identified, including Nkx2.2, Nkx6.1, Rfx6, Glis3, Insm1 and Neurod1; however, we still have an incomplete understanding of how these factors regulate the timing and mechanism of β cell fate induction since they are often expressed both early and throughout pancreas development and are not always restricted to the β cell lineage. For example, Nkx2.2, Nkx6.1 and Rfx6 are expressed in multipotent pancreatic progenitors *and* endocrine progenitors, in addition to their maintained expression in several of the mature endocrine lineages ([@bib5]; [@bib20]; [@bib32]; [@bib40]). Glis3 expression is first detected in the bipotent progenitor cells, but is then maintained in the preductal and endocrine progenitors, and ultimately restricted to the β, PP and ductal lineages ([@bib21]). Insm1 is similarly expressed in the pancreatic pre-endocrine cells, endocrine progenitor cells and is maintained in all endocrine cell types ([@bib12]; [@bib26]; [@bib29]). Lastly, *Neurod1* can be detected as early as E9.5 in the early glucagon and ghrelin producing cells, but predominantly becomes restricted first to endocrine progenitors and then is maintained in all endocrine lineages ([@bib2]; [@bib27]). Null mutations of all six of these transcriptional regulators cause neonatal lethality likely due to their severe defects in β cell development ([@bib12]; [@bib27]; [@bib29]; [@bib34]; [@bib39]; [@bib42]); however, it is unknown exactly when each of these factors exerts their functional role in β cell fate specification.

To gain a better understanding of both the timing and mechanism of β cell fate induction we chose to focus on the essential islet transcription factor, Nkx2.2. Nkx2.2 is a critical regulator of appropriate islet cell lineage specification during pancreagenesis; mice carrying an *Nkx2.2* null mutation form reduced numbers of α and β cells and instead form increased numbers of ghrelin-producing ε cells due to defects in cell lineage specification ([@bib34]; [@bib42]). Importantly, β cell fate specification is completely dependent on Nkx2.2 as no β cells are formed in mice carrying a null mutation in *Nkx2.2* (*Nkx2.2^KO^*) ([@bib42]). Nkx2.2 is co-expressed with Pdx1 throughout the pancreatic progenitor domain, but its expression becomes restricted to the Neurog3^+^ endocrine progenitor population ([@bib5]; [@bib20]; [@bib42]). Nkx2.2 also appears to function at or near the top of the regulatory cascade of transcription factors to specify β cell fate: The expression of *Neurog3, Nkx6.1*, *Rfx6* and *Neurod1* was significantly reduced in *Nkx2.2^KO^* progenitor populations ([@bib2], [@bib3]; [@bib7]) ([Table 1](#tbl1){ref-type="table"}), suggesting that Nkx2.2 functions within the pancreatic epithelium to influence the derivation of endocrine-committed cells that can enter the appropriate endocrine lineage pathways.10.7554/eLife.20010.002Table 1.*NKx2.2^Δendo^* and *Nkx2.2^KO^* E15.5 RNA-Seq - Gene expression changes in select transcription factors and pancreatic hormones.**DOI:** [http://dx.doi.org/10.7554/eLife.20010.002](10.7554/eLife.20010.002)***Nkx2.2^△^*^*endo* ^fold changeAdjusted p-value*Nkx2.2*^*KO* ^fold changeAdjusted p-valueTranscription factors**Arx2.163.26E-091.570.0031MafA0.113.39E-060.130.0040MafB0.431.31E-100.223.92E-38NeuroD10.8910.323.01E-23Neurog31.1110.590.0198Nkx6.10.7710.820.9684Pax41.0210.730.4762Pax60.361.07E-060.212.84E-30Pdx10.8811.250.7916Rfx61.0010.630.0013Sox90.9411.081**Pancreatic hormones**Gast0.192.16E-070.092.63E-09Gcg0.162.23E-120.014.64E-16Ghrl8.271.94E-316.436.72E-16Ins10.034.84E-240.004.32E-11Ins20.012.99E-550.001.48E-11Ppy10.084.99E-422.177.15E-05Sst1.1410.450.5130

The early expression of Nkx2.2 within the multipotent progenitor population, upstream of Neurog3 prompted us to determine whether Nkx2.2 also functioned downstream of Neurog3 to influence islet cell specification. We used *Neurog3-Cre; Nkx2.2^flox/flox^* (*Nkx2.2^△endo^*) mice to ablate Nkx2.2 specifically within the Neurog3^+^ endocrine progenitor lineage. Although Nkx2.2 is expressed upstream of Neurog3 and regulates *Neurog3* expression ([@bib3]; [@bib42]), deletion of *Nkx2.2* using precise Neurog3-based floxed gene inactivation resulted in severe endocrine defects similar to the *Nkx2.2^KO^* phenotype. Notably, unlike the *Nkx2.2^KO^* mice, *Neurog3* expression in the *Nkx2.2^△endo^* mice was not affected. This suggests that Nkx2.2-mediated endocrine specification is established within the endocrine lineage, downstream of *Neurog3* activation. Furthermore, unlike the *Nkx2.2^KO^* mice, expression of several essential islet cell transcription factors, including *Rfx6* and *Neurod1*, was unaffected. Co-occupancy analysis revealed significant overlap between Nkx2.2 direct targets and Rfx6 and Neurod1 bound genes. This indicates β cell formation may not be regulated by a simple linear transcriptional cascade that functions downstream of Nkx2.2, and implicates Nkx2.2 as an essential component of a modular β cell transcription network.

Results {#s2}
=======

*Nkx2.2* is efficiently ablated in *Nkx2.2^△endo^* mice {#s2-1}
-------------------------------------------------------

Nkx2.2 is expressed at the onset of pancreas development throughout the multipotent progenitor domain, but subsequently becomes restricted to the Neurog3^+^ endocrine progenitor population ([@bib20]). Furthermore, null mutations in *Nkx2.2* (*Nkx2.2^KO^*) lead to significantly reduced *Neurog3* RNA expression, although there is no corresponding change in Neurog3^+^ cell numbers ([@bib3]). To determine whether Nkx2.2 activity downstream of Neurog3 was also necessary for specific aspects of endocrine cell specification, *Neurog3-Cre; Nkx2.2^flox/flox^* or *Nkx2.2^flox/LacZ^; R26R-Tomato* (hereafter referred to as *Nkx2.2^△endo^*) mice were generated to ablate *Nkx2.2* specifically within the endocrine progenitor cells and their descendants ([@bib23]; [@bib25]; [@bib37]). Efficient deletion of *Nkx2.2* in the *Nkx2.2^△endo^* mice was demonstrated by a reduction in *Nkx2.2* mRNA expression at E15.5 and E18.5 ([Figure 1A](#fig1){ref-type="fig"}). Residual *Nkx2.2* gene expression at E15.5 likely reflects the *Nkx2.2* expression in pancreatic progenitor cells that are still present at this stage of development. Consistent with the decrease in *Nkx2.2* gene expression, Nkx2.2 protein was almost undetectable in the pancreas at E15.5 and postnatal day (P)0 ([Figure 1B,C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Activation of the *R26R-Tomato* allele was also used to monitor accurate Cre activity within the *Nkx2.2^△endo^* mice and, accordingly, Tomato^+^ (Tom^+^) cells were found specifically within the endocrine compartment ([Figure 1B,C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).10.7554/eLife.20010.003Figure 1.Nkx2.2 is ablated specifically in the endocrine lineage in *Nkx2.2^△endo^* mice.(**A**) Nkx2.2 gene expression is decreased at E15.5 (Control n = 3, *Nkx2.2^△endo^* n = 6) and E18.5 (Control n = 6, *Nkx2.2^△endo^* n = 4). (**B**--**C**) Immunostaining for Nkx2.2 shows decreased expression in *Nkx2.2^△endo^* mice at P0 (n = 3). (**D**--**E**) Immunostaining for Neurog3 shows no apparent changes in the Neurog3^+^ cell population at E15.5 (n = 3). (**F**) Endocrine compartment gene expression is unchanged at E15.5 (Control n = 3, *Nkx2.2^△endo^* n = 6) and E18.5 (Control n = 6, *Nkx2.2^△endo^* n = 4). (\*) p\<0.05; (\*\*\*) p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.20010.003](10.7554/eLife.20010.003)10.7554/eLife.20010.004Figure 1---figure supplement 1.Exocrine and endocrine compartment size is unaffected *Nkx2.2^△endo^* mice.(**A**--**B**) Immunostaining for Neurog3 shows no change in Neurog3^+^ cell number; ([**C**]{.smallcaps}--**D**) adjacent sections show decreased Nkx2.2^+^ cells in *Nkx2.2^△endo^* embryos at E15.5. (**E**--**F**) Immunostaining for Nkx2.2 shows decreased expression in *Nkx2.2^△endo^* embryos at E15.5 (n = 3). (**G**--**H**) Amylase immunostaining and Tomato^+^ cells are not changed in *Nkx2.2^△endo^* mice at P0 (n = 3). (**I**) Whole pancreas quantification of Tomato^+^ cells normalized to total pancreas area shows no change in *Nkx2.2^△endo^* mice at P0 (n = 3). A.U., arbitrary units.**DOI:** [http://dx.doi.org/10.7554/eLife.20010.004](10.7554/eLife.20010.004)

Deletion of *Nkx2.2* from the endocrine progenitor population did not affect the number of Neurog3-expressing endocrine progenitor cells and Neurog3 expression within the Tomato-labeled, Nkx2.2-deficient cells was maintained ([Figure 1D,E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). Deletion of Nkx2.2 did not appear to affect the earlier cell populations that give rise to endocrine progenitors since the expression of *Sox9*, an early progenitor marker that is expressed immediately upstream of *Neurog3* in the bipotent progenitor pool from which endocrine cells are derived, was unaffected ([Figure 1F](#fig1){ref-type="fig"}). Consistent with specific deletion of Nkx2.2 from the endocrine progenitor population, there were also no obvious changes in the exocrine lineage, as indicated by amylase expression ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Expression of pan-endocrine genes, such as *ChromograninA* (*Chga*), *Isl1*, and *Pax6* was also unchanged in the absence of *Nkx2.2* at E15.5, and the area and number of Tomato-labeled endocrine lineage cells was also unaffected in the *Nkx2.2^△endo^* mice at E15.5 and P0, suggesting endocrine compartment size was not decreased when Nkx2.2 was deleted from the endocrine progenitor cell ([Figure 1B,C,F](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

*Nkx2.2^△endo^* mice display similar endocrine defects as *Nkx2.2^KO^* mice {#s2-2}
---------------------------------------------------------------------------

Since Nkx2.2 is necessary for the establishment of proper endocrine cell ratios, we assessed the status of endocrine cell differentiation in the *Nkx2.2^△endo^* mice during the course of pancreas development. Similar to the *Nkx2.2^KO^* mice ([@bib34]; [@bib42]), *Nkx2.2^△endo^* mice displayed a reduction of insulin^+^ (Ins^+^) cells and glucagon^+^ (Gcg^+^) cells, and increased ghrelin^+^ (Ghrl^+^) cells at E15.5 and P0 ([Figure 2A--H](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Gastrin^+^ (Gast^+^) cells were decreased at E15.5 ([Figure 2I,J](#fig2){ref-type="fig"}), and no changes were observed in somatostatin^+^ (SST^+^) cell number at P0 ([Figure 2K--L](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Unlike the Nkx2.2^KO^ mice which lack all β cells, a small number of Ins^+^ cells were detected ([Figure 2A--L](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), which is possibly due to the inability of the *Neurog3-Cre* allele to completely inactivate *Nkx2.2*. Gene expression at E15.5 and E18.5 corresponded to changes in endocrine cell numbers. *Insulin (Ins1* and *Ins2*) and *glucagon* expression were significantly decreased; there was increased *ghrelin* expression, and no change in *somatostatin* gene expression at E15.5 and E18.5 ([Figure 2M](#fig2){ref-type="fig"}). *Gast* gene expression was also decreased at E15.5, but *Gast* expression was extinguished from both the wild type and mutant pancreata by E18.5 ([Figure 2M](#fig2){ref-type="fig"}), as previously observed ([@bib41]). Similar to the *Nkx2.2^KO^* mice, the *Nkx2.2^△endo^* mice die shortly after birth between P2 and P4 ([Figure 2N](#fig2){ref-type="fig"}).10.7554/eLife.20010.005Figure 2.*Nkx2.2^△endo^* mice recapitulate the *Nkx2.2^KO^* phenotype.(**A**--**H**) Ghrl^+^ cells are increased, Ins^+^ cells are greatly reduced, and Gcg^+^ cells are decreased at E15.5 and P0 in *Nkx2.2^△endo^* mice (n = 3). (**I**--**J**) Gast^+^ cells are reduced in *Nkx2.2^△endo^* embryos at E15.5 (n = 3). (**K**--**L**) SST^+^ cells are unchanged in *Nkx2.2^△endo^* mice at P0 (n = 3). (**M**) Hormone gene expression changes recapitulate *Nkx2.2^KO^* mice at E15.5 (Control n = 3, *Nkx2.2^△endo^* n = 6) and E18.5 (Control n = 6, *Nkx2.2^△endo^* n = 4). *Ppy* gene expression is increased at these time points. (**N**) *Nkx2.2^△endo^* mice die neonatally. (**O**) qRT-PCR confirms increased *Ppy* at E15.5 in *Nkx2.2^KO^* embryos (Control n = 3, *Nkx2.2^KO^* n = 3). (\*) p\<0.05; (\*\*) p\<0.01; (\*\*\*) p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.20010.005](10.7554/eLife.20010.005)10.7554/eLife.20010.006Figure 2---figure supplement 1.*Nkx2.2^△endo^* mice display endocrine specification defects at P0.(**A**--**D**) Low magnification images showing increased Ghrl^+^ cells, and decreased Ins^+^ cells and Gcg^+^ cells in *Nkx2.2^△endo^* mice at P0 (n = 3). (**E**) Whole pancreas quantification of Gcg^+^, Sst^+^, and Ghrl^+^ cells normalized to pancreas area at P0. *Nkx2.2^△endo^* mice display decreased Gcg^+^ cells, no change in Sst^+^ cells, and increased Ghrl^+^ cells (Control n = 3, *Nkx2.2^△endo^* n = 5). (\*) p\<0.05; (\*\*) p\<0.01. A.U., arbitrary units.**DOI:** [http://dx.doi.org/10.7554/eLife.20010.006](10.7554/eLife.20010.006)10.7554/eLife.20010.007Figure 2---figure supplement 2.PP cells are increased in *Nkx2.2^△endo^* mice.(**A**--**D**) Immunostaining for PP shows increased PP^+^ cells at E15.5 and P0 in *Nkx2.2^△endo^* mice (n = 3). Arrow indicates a PP^+^Ins^+^ cell. (**E**--**F**) Low magnification images showing increased PP^+^ cells at P0 in *Nkx2.2^△endo^* mice. (**G**) Whole pancreas quantification of Ins^+^ and PP^+^ cells normalized to the total number of Tom^+^ cells shows increased Ins^-^PP^+^Tom^+^ cells and decreased Ins^+^PP^-^Tom^+^ cells in *Nkx2.2^△endo^* mice at P0 (n = 3). No changes in Ins^+^PP^+^Tom^+^ cells are detected. (\*\*) p\<0.01; (\*\*\*) p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.20010.007](10.7554/eLife.20010.007)

Interestingly, we observed increased *pancreatic polypeptide* (*Ppy*) expression at E15.5 and E18.5 in *Nkx2.2^△endo^* embryos ([Figure 2M](#fig2){ref-type="fig"}). Although this was in contrast to previous studies in which we had observed decreased *Ppy* gene expression and PP^+^ cell numbers ([@bib7]; [@bib34]; [@bib42]), we confirmed that there was similar upregulation of *Ppy* in the *Nkx2.2^LacZ/LacZ^* (*Nkx2.2^KO^*) pancreas ([@bib5]) compared to the *Nkx2.2^△endo^* pancreas, although the magnitude of upregulation was greater in the *Nkx2.2^△endo^* embryos ([Figure 2M,O](#fig2){ref-type="fig"}). In *Nkx2.2^△endo^* mice, upregulation of *Ppy* RNA correlated with changes in protein; immunostaining revealed increased PP^+^ cells at both E15.5 and P0 ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). While some Ins^+^PP^+^ cells could be observed (arrow in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), there was no significant difference between *Nkx2.2^△endo^* mice and controls ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), suggesting that similar to the ghrelin-expressing cells, whose increased numbers were due to altered ε cell specification at the expense of β cell specification, the excess PP cells did not arise from misexpression of PP in β cells or as a result of β cell reprogramming. We speculate that the novel *Ppy* phenotype in the *Nkx2.2^△endo^* and *Nkx2.2^KO^* mice may result from a change in mouse strain background (see Discussion).

*Nkx2.2^△endo^* and *Nkx2.2^KO^* mice share important gene expression changes {#s2-3}
-----------------------------------------------------------------------------

It was somewhat unexpected that the restricted deletion of *Nkx2.2* in the Neurog3^+^ progenitor cells resulted in a phenotype that was remarkably similar to the *Nkx2.2^KO^* mice, which lacked *Nkx2.2* throughout pancreas development. To more precisely determine the similarities and differences between the *Nkx2.2^△endo^* and *Nkx2.2^KO^* mice during the process of endocrine cell differentiation, we performed RNA-Seq analysis on whole pancreata derived from *Nkx2.2^△endo^* embryos, *Nkx2.2^KO^* embryos, and their respective littermate controls at E15.5, a time of relatively high Neurog3^+^ cell abundance. Consistent with their similar phenotypes, there was significant overlap (120 genes, p-value \<2.2e-16, [Figure 3A](#fig3){ref-type="fig"}) between the differentially expressed genes (adjusted p-value \<0.05), including genes encoding pancreatic hormones ([Figure 3B](#fig3){ref-type="fig"}) and important α and β cell regulatory factors, such as *Mafa* and *Mafb* ([Figure 3C,D](#fig3){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Furthermore, several transcription factor genes expressed in endocrine progenitors and involved in β cell specification, such as *Nkx6.1*, *Pax4*, and *Pdx1*, that were unchanged *Nkx2.2^KO^* embryos at E15.5 were also not affected in *Nkx2.2^△endo^* pancreas at this early time point ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}).10.7554/eLife.20010.008Figure 3.*Nkx2.2^△endo^* and *Nkx2.2^KO^* embryos have shared and distinct gene expression changes.(**A**) Comparison of *Nkx2.2^△endo^* and *Nkx2.2^KO^* RNA-Seq experiments shows significant overlap of dysregulated genes (adjusted p-value \<0.05.) (**B**) RNA-Seq reveals similar changes in hormone expression in *Nkx2.2^△endo^* and *Nkx2.2^KO^* embryos, relative to littermate controls. (**C**) RNA-Seq shows decreases in *Mafa* and *Mafb* gene expression in *Nkx2.2^△endo^* and *Nkx2.2^KO^* embryos, relative to littermate controls. (**D**) qRT-PCR confirms decreases in *Mafa* and *Mafb* at E15.5 (Control n = 3, *Nkx2.2^△endo^* n = 6) and E18.5 (Control n = 6, *Nkx2.2^△endo^* n = 4). (**E**) RNA-Seq shows unchanged *Neurog3*, *Neurod1*, and *Rfx6* gene expression in *Nkx2.2^△endo^* embryos; Nkx2.2^KO^ embryos show downregulation, relative to littermate controls. (**F**) qRT-PCR confirms RNA-Seq results. *Neurod1* and *Rfx6* gene expression are unchanged at E15.5 and E18.5. *Neurog3* gene expression is unchanged at E15.5 and increased at E18.5. (E15.5: Control n = 3, *Nkx2.2^△endo^* n = 3--6; E18.5: Control n = 5--6, *Nkx2.2^△endo^* n = 4). (**G**--**H**) Neurog3^+^ cells are not detected at P0 (n = 3). Mutant RNA-Seq data was normalized to littermate controls; dotted lines refer to 1.0 fold change. (\*) p\<0.05; (\*\*) p\<0.01; (\*\*\*) p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.20010.008](10.7554/eLife.20010.008)10.7554/eLife.20010.009Figure 3---source data 1.*Nkx2.2^△endo^* and *Nkx2.2^KO^* E15.5 RNA-Seq: Genes showing significant differential expression in both *Nkx2.2^△endo^* and *Nkx2.2^KO^* mice (120 genes).**DOI:** [http://dx.doi.org/10.7554/eLife.20010.009](10.7554/eLife.20010.009)10.7554/eLife.20010.010Figure 3---source data 2.*Nkx2.2^△endo^* and *Nkx2.2^KO^* E15.5 RNA-Seq: Genes showing significant differential expression in only *Nkx2.2^KO^* mice (325 genes).**DOI:** [http://dx.doi.org/10.7554/eLife.20010.010](10.7554/eLife.20010.010)10.7554/eLife.20010.011Figure 3---source data 3.*Nkx2.2^△endo^* and *Nkx2.2^KO^* E15.5 RNA-Seq: Genes showing significantly differential expression in only *Nkx2.2^△endo^* mice (55 genes).**DOI:** [http://dx.doi.org/10.7554/eLife.20010.011](10.7554/eLife.20010.011)10.7554/eLife.20010.012Figure 3---figure supplement 1.Many islet transcription factor genes are relatively unchanged in Nkx2.2deltaendo embryos.(**A**) RNA-Seq at E15.5 shows no changes in *Nkx6.1*, *Pax4*, or *Pdx1* gene expression in *Nkx2.2^△endo^* and *Nkx2.2^KO^* embryos, relative to respective littermate controls; dotted line refers to 1.0 fold change. (**B**) qRT-PCR confirms no changes in *Nkx6.1*, *Pax4*, or *Pdx1* at E15.5 (Control n = 3, *Nkx2.2^△endo^* n = 6), no changes in *Nkx6.1* or *Pax4* at E18.5, and decreased *Pdx1* at E18.5 in *Nkx2.2^△endo^* mice (Control n = 6, *Nkx2.2^△endo^* n = 4). (\*) p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.20010.012](10.7554/eLife.20010.012)

Key islet regulators Neurog3, Neurod1, and Rfx6 are retained in *Nkx2.2^△endo^* mice {#s2-4}
------------------------------------------------------------------------------------

Notably, in sharp contrast to the *Nkx2.2^KO^* mice, which have reduced *Neurog3*, *Neurod1*, and *Rfx6* ([@bib2], [@bib3]; [@bib7]) ([Table 1](#tbl1){ref-type="table"}), expression of *Neurog3*, *Neurod1*, and *Rfx6* were unaffected in the *Nkx2.2^△endo^* mice ([Figure 3E](#fig3){ref-type="fig"}). We performed qRT-PCR analysis to confirm the maintenance of *Neurog3*, *Neurod1*, and *Rfx6* gene expression in E15.5 and E18.5 *Nkx2.2^△endo^* mice ([Figure 3F](#fig3){ref-type="fig"}). Although *Neurog3* mRNA appeared to be modestly increased at E18.5 in the *Nkx2.2^△endo^* mice ([Figure 3F](#fig3){ref-type="fig"}), Neurog3^+^ cells could not be detected by immunostaining in perinatal animals ([Figure 3G,H](#fig3){ref-type="fig"}). These results suggest that although Nkx2.2 regulates *Neurog3*, *Neurod1*, and *Rfx6* expression within the pancreatic progenitor population, regulation of *Neurog3*, *Neurod1*, and *Rfx6* expression within the endocrine progenitor cells becomes independent of Nkx2.2. Furthermore, this suggests that maintenance of *Neurog3*, *Neurod1*, and *Rfx6* expression in the absence of *Nkx2.2* is not sufficient for appropriate islet lineage specification.

Nkx2.2 direct target genes are simultaneously bound by Rfx6 and/or Neurod1 {#s2-5}
--------------------------------------------------------------------------

The finding that β cell specification was disrupted, even though *Neurog3*, *Neurod1* and *Rfx6* expression remained intact, could indicate that Nkx2.2 functions as an obligate co-factor for these proteins in the regulation of β cell specification. This is supported by our previous observation that Nkx2.2 cooperated with Neurog3 to regulate the expression of Neurod1 ([@bib2]). To determine whether there was a general requirement for a cooperative role for Nkx2.2 within the known β cell specification regulatory pathways, we assessed whether Nkx2.2 co-regulated the β cell program with Rfx6 and Neurod1. Nkx2.2 bound and regulated genes were identified by cross-referencing the differentially expressed genes in the Nkx2.2^△endo^ RNA-Seq (adjusted p-value \<0.05, [Figure 3](#fig3){ref-type="fig"}) with an Nkx2.2 ChIP-Seq performed on the MIN6 β cell line (GSE79725) ([@bib10]). Notably, the majority of the genes regulated by Nkx2.2 appeared to be primary targets: 169/175 of the significantly regulated genes were bound by Nkx2.2 within 100 kb of of their respective transcriptional start sites (TSS) ([Figure 3A](#fig3){ref-type="fig"}; [Figure 4A,C](#fig4){ref-type="fig"}). We then compared the Nkx2.2 direct targets to genes bound by either Rfx6 (GSE62844; 9406 genes) or Neurod1 (GSE30298; 5003 genes) ([@bib33]) ([@bib43]). This analysis revealed significant overlap of Rfx6 binding near Nkx2.2 target genes (120 genes, p-value \<2.2e-16, [Figure 4A](#fig4){ref-type="fig"}) and gene ontology (GO) analysis indicated significant representation of genes related to hormone secretion ([Figure 4B](#fig4){ref-type="fig"}). Analysis of Neurod1 bound genes revealed similar overlap with Nkx2.2 targets (92 genes, p-value \<2.2e-16, [Figure 4C](#fig4){ref-type="fig"}), and GO analysis identified significant representation of insulin secretion genes ([Figure 4D](#fig4){ref-type="fig"}). Furthermore, greater than 75% of the 92 genes simultaneously bound by Nkx2.2 and Neurod1 in the same or nearby regulatory regions were also bound by Rfx6 (72 genes, [Figure 4E](#fig4){ref-type="fig"}), demonstrating novel regulatory co-operation between these three transcription factors.10.7554/eLife.20010.013Figure 4.Nkx2.2 bound and regulated genes are co-bound by Rfx6 and Neurod1.(**A**) Comparison of Nkx2.2 bound and regulated genes and Rfx6 bound genes (**B**) Gene ontology (GO) analysis of genes with Nkx2.2 binding and regulation and Rfx6 binding. (**C**) Comparison of Nkx2.2 bound and regulated genes and Neurod1 bound genes. (**D**) GO analysis of genes with Nkx2.2 binding and regulation and Neurod1 binding. (**E**) Comparison between Nkx2.2 bound and regulated and Rfx6 bound genes with Nkx2.2 bound and regulated and Neurod1 bound genes. 72 genes are shared. (**F**) RNA-Seq shows decreased *Mlxipl*, *Mafa*, *Gast*, and *G6pc2* expression at E15.5 in *Nkx2.2^△endo^* embryos. Dotted line refers to 1.0 fold change. (\*\*\*) p\<0.001. (**G**) Nkx2.2, Rfx6, and Neurod1 show overlapping binding peaks at *Mlxipl* locus (mm9 chr5:135,580,783--135,615,792 shown). (**H**) Nkx2.2 and Neurod1 show overlapping binding peaks at a region upstream of *Mafa* (mm9 chr15:75,577,046--75,587,657 shown). (**I**) Nkx2.2 and Rfx6 show overlapping binding peaks upstream of *Gast* and within intron 1 (mm9 chr11:100,186,915--100,199,407 shown). (**J**) Non-overlapping Nkx2.2, Rfx6, and Neurod1 binding peaks near *G6pc2* locus (mm9 chr2:69,052,146--69,070,781 shown).**DOI:** [http://dx.doi.org/10.7554/eLife.20010.013](10.7554/eLife.20010.013)10.7554/eLife.20010.014Figure 4---source data 1.Nkx2.2 bound and regulated genes that are also Rfx6 bound (120 genes) or NeuroD1 bound (92 genes).**DOI:** [http://dx.doi.org/10.7554/eLife.20010.014](10.7554/eLife.20010.014)10.7554/eLife.20010.015Figure 4---source data 2.Nkx2.2 bound and regulated genes that are also Rfx6 bound and NeuroD1 bound (72 genes).**DOI:** [http://dx.doi.org/10.7554/eLife.20010.015](10.7554/eLife.20010.015)

Although it is possible that at some genomic loci the Nkx2.2/Neurod1/Rfx6 co-regulation of important β cell genes could be due to direct protein-protein interactions, the respective binding sites were often not closely clustered. Inspection of the Nkx2.2, Rfx6, and Neurod1 ChIP-Seq data revealed a variety of co-occupancy patterns in the regulatory elements associated with several candidate Nkx2.2-regulated genes ([Figure 4F](#fig4){ref-type="fig"}). For example, all three transcription factors showed overlapping binding peaks at the *Mlxipl* locus ([Figure 4G](#fig4){ref-type="fig"}). However, at a region upstream of *Mafa*, only Nkx2.2 and Neurod1 were present ([Figure 4H](#fig4){ref-type="fig"}); whereas Nkx2.2 and Rfx6 co-bound at the *Gast* locus ([Figure 4I](#fig4){ref-type="fig"}). In addition, Nkx2.2, Rfx6, and Neurod1 all bound near *G6pc2*; however, these peaks were present at distinct locations flanking the gene ([Figure 4J](#fig4){ref-type="fig"}). These results suggest that while Nkx2.2, Rfx6, and Neurod1 are individually critical for the regulation of the islet cell program, it is their cooperative function that may be required for the appropriate activation of a number of essential β cell genes.

Discussion {#s3}
==========

The spatiotemporal progression of islet cell specification is not well understood. While many transcription factors that are essential for this process are well-characterized, their sustained expression throughout development and in several different cell types has made it challenging to identify the timing of their function. Nkx2.2 is expressed within the Pdx1^+^ pancreatic multipotent progenitor population and its expression is maintained throughout pancreas development, gradually becoming restricted to the endocrine cell lineages ([@bib5]; [@bib20]; [@bib42]). Global deletion of *Nkx2.2* causes the reduction of many essential regulatory factors, including *Neurog3, Neurod1* and *Rfx6* ([@bib2], [@bib3]; [@bib7]) ([Table 1](#tbl1){ref-type="table"}) and mis-specification of all endocrine lineages, except the somatostatin-expressing δ cells. The fact that these mice completely fail to form β cells, combined with the reduced expression of many β cell regulatory factors provided a strong argument for positioning Nkx2.2 at or near the top of the hierarchy for regulation of β cell specification. In this study, we ablated Nkx2.2 specifically within the endocrine progenitor lineage to determine whether Nkx2.2 also functions downstream of Neurog3 in regulating islet cell specification. Surprisingly, we found similar endocrine lineage changes in *Nkx2.2^△endo^* mice compared to *Nkx2.2^KO^* mice, including the failure to form β cells ([@bib42]) (Schematized in [Figure 5](#fig5){ref-type="fig"}). However, unlike the *Nkx2.2^KO^* mice, expression of the essential β cell transcription factors *Neurog3*, *Rfx6*, and *Neurod1* was unaffected, suggesting that although Nkx2.2 regulates these factors in the pancreatic progenitor population, reduction of *Neurog3*, *Neurod1* and *Rfx6* expression is not an obligate step in the mis-specification of islet fates. This may indicate that although Neurog3, Neurod1 and Rfx6 are essential for specifying the β cell program, Nkx2.2 activity must be preserved to facilitate the functional integrity of the β cell regulatory pathway ([Figure 5](#fig5){ref-type="fig"}). Furthermore, co-occupancy analysis revealed significant overlap of Nkx2.2 direct targets with Rfx6 and Neurod1 binding, suggesting cooperative transcriptional regulation of these factors.10.7554/eLife.20010.016Figure 5.Model of transcriptional networks involved in endocrine cell specification in wildtype (WT), *Nkx2.2^KO^*, and *Nkx2.2^△endo^* conditions.Neurog3, Neurod1, and Rfx6 are not sufficient to allow for β cell specification in the absence of Nkx2.2 in *Nkx2.2^△endo^* mice. The size of the circles represents the proportion of cell numbers compared to wildtype.**DOI:** [http://dx.doi.org/10.7554/eLife.20010.016](10.7554/eLife.20010.016)

Given its early expression in the multipotent progenitor population, it was unexpected that deletion of Nkx2.2 from the Neurog3^+^ cells was sufficient to recapitulate the *Nkx2.2^KO^* phenotype. However, it is consistent with a recent study showing that *Neurog3-Cre; Rfx6^flox/flox^* mice display β cell loss similar to the *Rfx6^null^* mice ([@bib33]). Similarly, Nkx6.1 functions downstream of Neurog3, with *Neurog3-Cre; Nkx6.1^flox/flox^*mice displaying defective β cell differentiation ([@bib36]). These studies provide evidence that the endocrine progenitor cell, downstream of Neurog3 induction, is the primary site of islet cell specification. However, it is still possible that preprogramming of this population does occur, but that the respective programs can be over-written once the cell has formed. The importance of Nkx2.2 function downstream of Neurog3 expression is also consistent with the timing of NKX2.2 in human islets; unlike mice, NKX2.2 is only first detected after the appearance of NEUROG3 progenitors ([@bib17]). However, while Nkx2.2 function within the mouse Pdx1^+^ pancreatic progenitor was not sufficient to allow correct islet cell specification and β cell formation, further studies would be required to determine whether Nkx2.2 has additional functions at this earlier stage of pancreas development.

Although deletion of Nkx2.2 in the endocrine progenitor population appears to grossly phenocopy the *Nkx2.2^KO^* phenotype, the phenotypes were not as severe as observed in the *Nkx2.2^KO^* mice. Although this may be due to the efficiency of Cre-mediated deletion of the *Nkx2.2* allele, it could also suggest that there are partially redundant functions of Nkx2.2 in the pancreas progenitor and endocrine progenitor populations. In addition, there were over 300 genes significantly altered in *Nkx2.2^KO^* pancreas that were unchanged in the *Nkx2.2^△endo^* mice ([Figure 3A](#fig3){ref-type="fig"}; Table 4). Again, this could be due to the more penetrant phenotype associated with the *Nkx2.2^KO^* allele or could suggest that Nkx2.2 may have additional non-redundant functions upstream of Neurog3. Future studies in which we are able to conditionally re-express Nkx2.2 in the Neurog3 population in an *Nkx2.2^KO^* background, similar to the Neurog3 replacement studies by [@bib18], would possibly reveal these functions. There were also a small number of genes whose expression only appeared to be changed in the *Nkx2.2^△endo^* mice ([Figure 3A](#fig3){ref-type="fig"}, Table 3). This is more difficult to explain unless there are some novel, compensatory gene changes that can occur in the remaining cell populations. Assessment of the identity of the differentially affected genes in either the *Nkx2.2^KO^* or *Nkx2.2^△endo^* mice did not reveal any obvious mechanistic insights.

Several previous studies of the *Nkx2.2^KO^* mice demonstrated that Nkx2.2 is essential for the correct specification of all endocrine cell populations, except δ cells ([@bib5]; [@bib25], [@bib24]; [@bib34]; [@bib42]). These earlier studies also revealed that in the absence of Nkx2.2 there was mis-specification of the endocrine lineages, rather than reprogramming of the endocrine populations following their formation. Alternatively, deletion of the conserved tinman (TN) domain of Nkx2.2 resulted in both aberrant endocrine cell specification and reprogramming of β cells to the α cell fate ([@bib31]). Furthermore, recent studies in which *Nkx2.2* was deleted from β cells after their specification resulted in β cell reprogramming into alternative endocrine lineages and the appearance of islet cells expressing more than one hormone ([@bib10]). Interestingly, the phenotype of the *Nkx2.2^△endo^* mice most closely resembles the Nkx2.2^KO^ mice, and we do not see evidence of reprogramming or multi-hormonal expressing (transient or stable) endocrine cells in the mutant islets. However, since we are unable to genetically lineage trace the α or β cell populations in the *Nkx2.2^△endo^* mice, we cannot completely rule out the possibility that reprogramming of the α or β cells contributes to the elevated number of ε or PP cells.

Comparison of Nkx2.2 direct targets with Rfx6 and Neurod1 binding revealed co-occupancy of these factors in the same or nearby enhancer elements located within proximity of an endocrine-related gene. While ChIP-Seq analyses can reveal novel insights into the transcriptional regulation of cell fate, these analyses were performed on chromatin isolated from the immortalized MIN6 β cell line in order to isolate sufficient material for the assay. It is important to note that although we only focused on potential gene targets that were dysregulated in the *Nkx2.2^△endo^* pancreas, transcription factor binding in MIN6 cells may not accurately reflect binding in embryonic endocrine progenitor cells. Furthermore, our population-based transcriptome analysis is limited by the cell type heterogeneity present in the E15.5 pancreas, particularly when gene changes that are present in both progenitor populations and downstream sub-lineages may be represented. Future studies will benefit from single-cell RNA-Seq and ChIP-Seq analysis that will allow us to parse out the differential gene changes and transcription factor binding in the Nkx2.2-deficient endocrine progenitor cells.

We were surprised to observe an increase in the PP population of *Nkx2.2^△endo^* mice. Since re-evaluation of *Ppy* expression in the *Nkx2.2^KO^* mice revealed a similar phenotype, the increase in PP is likely not due to a unique function of Nkx2.2 in the pancreatic progenitor to specify PP cells. The best explanation for the discrepant PP phenotype is that we moved the *Nkx2.2 null* allele to a C57Bl6/J background for this study. The upregulation of PP is also interesting since it parallels the increase we observed with ε cells. Consistent with the observation that a subset of the PP population is derived from Ghrl-expressing ε cells ([@bib4]), PP^+^Ghrl^+^ cells can be infrequently found in *Nkx2.2^△endo^* mice at P0 (data not shown). Furthermore, we observe an upregulation of *Arx* expression, which has also previously been shown to induce enhanced PP cell formation ([@bib8]). We are unable to determine whether these altered islet cell ratios are similarly due to β cell transdifferentiation events since the *Neurog3-Cre* labels all islet cell lineages.

Similar to many other developmental pathways, β cell specification involves the function of numerous transcription factors, some of which are expressed early and throughout tissue formation. Our results identify a novel critical window for Nkx2.2-mediated regulation of islet cell specification within the Neurog3 lineage following induction of Neurog3. Furthermore, although Nkx2.2 appears to function near the top of the islet transcriptional hierarchy, we demonstrate that maintained Nkx2.2 activity is also a necessary component of the regulatory networks functioning downstream of Neurog3 to induce β cell specification. Our discovery that different combinations of the set of transcription factors analyzed in this study directly regulate important genes in the β cell pathways raises important questions about the complex nature of cell-specific gene regulation that may have important implications for β cell induction, maturation and function. Furthermore, while previous research has focused on the initial expression of β cell factors, future studies may benefit by ensuring the prolonged and combinatorial expression of these factors to recapitulate in vivo development and allow cooperative induction of target genes.

Materials and methods {#s4}
=====================

Animal maintenance {#s4-1}
------------------

Mice were maintained on a C57BL/6J background (The Jackson Laboratory). *Neurog3-Cre* (RRID:[IMSR:JAX:005667](https://scicrunch.org/resolver/IMSR:JAX:005667))*, Nkx2.2^flox/flox\ or\ flox/LacZ^* (RRID:[MGI:5544100](https://scicrunch.org/resolver/MGI:5544100); RRID:[BCBC_240](https://scicrunch.org/resolver/BCBC_240)), and *R26R-Tomato* (B6.Cg-*Gt(ROSA)26-Sor^tm14(CAG-tdTomato)Hze^*/J; RRID:[IMSR:RMRC13135](https://scicrunch.org/resolver/IMSR:RMRC13135)) mice were genotyped as previously published ([@bib5]; [@bib23]; [@bib25]; [@bib37]). *Nkx2.2^LacZ/La^*^cZ^ mice were genotyped as previously published ([@bib5]). Both Nkx2.2^-/-^ and Nkx2.2^LacZ/LacZ^ mice are referred to as Nkx2.2^KO^ mice in this paper ([@bib5]). Animal maintenance and procedures were conducted in accordance with a Columbia University Institutional Animal Care and Use Committee approved protocol (AAAG3206). To minimize animal usage while allowing for statistical analysis, a minimum of three independent embryos or animals were assessed for each experiment. The *R26-tdTomato* allele was occasionally leaky. Any embryos or mice with widespread Tomato expression and/or were determined to have the recombined allele (by PCR analysis) outside of the endocrine pancreas were excluded from the study.

Immunohistochemistry {#s4-2}
--------------------

### Fixation {#s4-2-1}

Samples were fixed in 4% paraformaldehyde (PFA). E15.5 embryos were fixed for 3 hr (h) at 4°C, and P0 neonates were fixed overnight at 4°C. Samples were washed in phosphate-buffered saline (PBS), and then transferred to 30% sucrose/PBS overnight at 4°C. Samples were embedded and frozen in optimum cutting temperature (O.C.T.) and stored at −80°C. 8 µm sections were taken and stored at −80°C.

### Staining {#s4-2-2}

Sections were washed in PBS and 0.1% Triton/PBS (PBST) and blocked in 2% donkey serum (DS)/PBST for 30 min (min) at room temperature (RT). The primary antibody was diluted in 2% DS/PBST and incubated on sections overnight at 4°C. Sections were washed in PBS and PBST and incubated 2--3 hr at RT with secondary antibody (Jackson Immuno Research, West Grove, PA) diluted in 2% DS/PBST at 1:500. Sections were washed in PBS and PBST and incubated with DAPI (Invitrogen TD21490) diluted in PBS at 1:1000 for 15 min at RT. Sections were washed in PBS and mounted with fluorescent mounting medium (DAKO Cat\# S3023; Agilent Technologies, Santa Barbara, CA).

### Primary antibodies {#s4-2-3}

Guinea pig α-Insulin (Dako Cat\# A0564 RRID:[AB_10013624](https://scicrunch.org/resolver/AB_10013624),1:500), rabbit α-Nkx2.2 (Sigma-Aldrich, St. Louis MO; Cat\# HPA003468 RRID:[AB_1079490](https://scicrunch.org/resolver/AB_1079490), 1:400), goat α-Ghrelin (Santa Cruz Biotechnology, Dallas TX; Cat\# sc-10368 RRID:[AB_2232479](https://scicrunch.org/resolver/AB_2232479), 1:500), rabbit α-Glucagon (Dako Cat\# A0565 RRID:[AB_10013726](https://scicrunch.org/resolver/AB_10013726), 1:800), rabbit α-Pancreatic Polypeptide (Innovative Research, Novi, MI; Cat\# 18--0043 RRID:[AB_140259](https://scicrunch.org/resolver/AB_140259), 1:200), guinea pig α-Pdx1 (Beta cell biology consortium (BCBC), 1:400), rabbit α-Amylase (Sigma-Aldrich, 1:500), rabbit α-Somatostatin (Phoenix Pharmaceuticals, Burlingame, CA; 1:200), rabbit α-Gastrin (Cell Marque, Rocklin, CA; 1:300). Rabbit α-Neurog3 (BCBC, 1:200) was used following an antigen retrieval step.

### Microscopy {#s4-2-4}

Images were taken using a Zeiss Confocal LSM 710 microscope and processed with Zen, ImageJ, and Adobe Photoshop software.

### Cell quantification {#s4-2-5}

For each neonate, every twentieth section was analyzed for insulin^+^, pancreatic polypeptide^+^, glucagon^+^, somatostatin^+^, ghrelin^+^, and Tomato^+^ cell quantification throughout the entire pancreas. Tiled images were taken at 20x objective with a Leica fluorescent microscope (DM5500/MZ16F) and processed with LAF software. Cells were counted and normalized to the total number of Tomato^+^ cells or total pancreatic area measured in arbitrary units using ImageJ software. An n ≥ 3 biological replicates (individual pancreata from different animals) were used. All values are expressed as mean ± SEM. Statistical analysis was performed using two-tailed student's unpaired *t*-test since independent animals were used in the analysis. Significance was achieved with p-value \<0.05.

RNA analysis {#s4-3}
------------

### RNA extraction {#s4-3-1}

Whole pancreata were dissected in PBS and transferred to RNA*later* (Ambion AM7021). Pancreata were incubated at 4°C overnight and stored at −20°C until RNA extraction. Pancreata were homogenized and total RNA was isolated following the Qiagen RNeasy Mini kit.

### Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis {#s4-3-2}

A normalized starting quantity of RNA (200 ng-1 µg) isolated from whole pancreas and random hexamers were used to synthesize cDNA following the SuperScript III reverse transcriptase protocol (Invitrogen 18080--044). qRT-PCR was performed using 200 ng cDNA and master mix (Eurogentec) and analyzed using the BioRad CFX96 Real-Time System. Genes were normalized to *CyclophilinB* (probe 5': tggtacggaaggtggag, forward primer 5': gcaaagttctagagggcatgga, reverse primer 5': cccggctgtctgtcttggt) and to littermate controls. An n ≥ 3 biological replicates (individual pancreata from different animals) were used at all ages; technical replicates were also completed in triplicate during qRT-PCR plate preparation. All values are expressed as mean ± SEM. Statistical analysis was performed using two-tailed student's unpaired *t*-test since independent animals were used in the analysis. Significance was achieved with p-value \<0.05.

#### Applied Biosystems TaqMan AODs {#s20}

*Insulin1* (Mm01950294_s1), *Insulin2* (Mm00731595_gH), *Glucagon* (Mm00801712_m1), *Pancreatic polypeptide* (Mm00435889_m1), *Ghrelin* (Mm00445450_m1), *Somatostatin* (Mm00436671_m1), *Gastrin* (Mm00439059_g1), *ChromograninA* (Mm00514341_m1), *Arx* (Mm00545903_m1), *Pdx1* (Mm00435565_m1), *Pax6* (Mm00443081_m1), *Isl1* (Mm00517585_m1), *Sox9* (Mm00448840_m1), *Pax4* (Mm01159036_m1).

#### Applied Biosystems Primer/TaqMan Probe sets {#s21}

*Nkx2.2* (probe 5': ccattgactctgccccatcgctct, forward primer 5': cctccccgagtggcagat, reverse primer 5': gagttctatcctctccaaaagttcaaa), *Neurogenin3* (probe 5': cctgcgcttcgcccacaact, forward primer 5': gacgccaaacttacaaag, reverse primer 5': gtcagtgcccagatgt), *Nkx6.1* (probe 5': tctggttccagaaccgcagga, forward primer 5': cggagagtcaggtca, reverse primer 5': tgcgtgcttctttctc), *Mafa* (probe 5': cggcgcacgctcaagaaccg, forward primer 5': catccgactgaaacagaag, reverse primer 5': ctcgctctccagaatgtgccgctgc), *Mafb* (probe 5': cgcgtccagcagaaacatcacc, forward primer 5': ccagtcgtgcaggtat, reverse primer 5': tgcgtcttctcgttctc), *Neurod1* (probe: ABI 185747095, forward primer 5': ccagcccactaccaatttgg, reverse primer 5': gggttctgctcaggcaagaa).

### RNA-sequencing (RNA-Seq) {#s4-3-3}

RNA was isolated from whole pancreata at E15.5 from *Nkx2.2^△endo^* (n = 3 biological replicates), *Nkx2.2^KO^* (n = 3 biological replicates), and respective littermate control embryos (n = 3 biological replicates for each mutant). Total RNA concentration and quality were measured using the Agilent Bioanalyzer RNA Nano chip. Library preparation was performed using Illumina TruSeq RNA prep kit. Libraries were then sequenced using Illumina HiSeq2000 at the Columbia Genome Center. RNA-Seq was performed with 30 million single end 100 bp reads. RTA (Illumina) was used for base calling and CASAVA (version 1.8.2) was used for converting BCL to fastq format, coupled with adaptor trimming. Reads were mapped to a reference genome (Mouse: UCSC/mm9) using Tophat ([@bib45]) (version 2.0.4) with four mismatches (--read-mismatches = 4) and 10 maximum multiple hits (--max-multihits = 10). Relative abundance (expression level) of genes and splice isoforms was determined using cufflinks ([@bib46]) (version 2.0.2) with default settings. Differentially expressed genes were calculated using Deseq ([@bib1]). Dataset overlap was determined with a Fisher's Exact test; significance was achieved with p-value \<0.05. Data is available at GSE80444: reviewer link - (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=izyriugqnbmdpmp&acc=GSE80444>).

### ChIP-Sequencing (ChIP-Seq) comparative analysis {#s4-3-4}

Nkx2.2 ([@bib10]) (GSE79725), Rfx6 ([@bib33]) (GSE62844), and Neurod1 ([@bib43]) (GSE30298) ChIP-Seq datasets were aligned to mm9 and visualized using IGV ([@bib35]; [@bib44]). Rfx6 bound genes were defined as genes containing Rfx6 binding within 100 kb of of their transcriptional start site (TSS) ([@bib33]; GSE62844). Neurod1 bound genes were defined as those containing Neurod1 binding within 100 kb of TSS ([@bib43]) (GSE30298). Nkx2.2 bound genes were defined as those containing Nkx2.2 binding within 100 kb of TSS ([@bib10]) (GSE79725). Nkx2.2 direct targets were determined by cross-referencing the *Nkx2.2^△endo^* RNA-Seq data (adjusted p-value \<0.05, GSE80444; <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=azcbauygvrsznaf&acc=GSE79785>) with the Nkx2.2 bound genes ([@bib10]). Dataset overlap was determined with a Fisher's Exact test; significance was achieved with p-value \<0.05. Gene ontology (GO) analysis was performed ([@bib11]).
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Summary:

This manuscript investigates the spatio-temporal requirements for the transcription factor Nkx2.2 in pancreatic endocrine cells. To do this, the authors ablate Nkx2.2 specifically in endocrine progenitor cells using Ngn3-Cre (called *Nkx2.2^Δendo^*), and compare the resulting phenotype with that of the global Nkx2.2 KO. They find that the endocrine-specific KO largely recapitulates the global KO phenotype in the pancreas, including severe β cell deficiency, establishing that Nkx2.2 is required to orchestrate β cell formation in progenitor cells already committed to an endocrine fate -- in other words downstream to Neurog3 (Ngn3).

This is interesting as Nkx2.2 has been proposed as an early upstream regulator of Neurog3 and other key β cell transcription factors (Rfx6 and NeuroD1), based on the global KO and expression data, but Neurog3, Rfx6 and NeuroD1 expression were not affected in the Nkx2.2endo pancreas. This suggests that although Nkx2.2 is important for expression of Neurog3, Rfx6 and NeuroD1, its main function is downstream to these factors.

The authors then investigate the relationship between Nkx2.2, Rfx6 and NeuroD1 in regulation of β cell fate, through analysis of existing ChIPseq and new RNAseq data, demonstrating co-binding of 2 or more of these transcription factors at a high proportion of Nkx2.2 targets. From this, they conclude that in endocrine progenitors Nkx2.2 functions as an essential component of a modular network including Rfx6 and NeuroD1, which is required for pancreatic β cell fate.

Overall this is a straightforward genetic analysis that has led to a surprising and interesting finding on the wiring of transcriptional regulators of β cell development, placing the key function of Nkx2.2 much later than previously thought.

Essential revisions:

1\) Please include in [Figure 1](#fig1){ref-type="fig"} quantitative data showing that the area of tomato expression is equivalent in the control and Nkx2.2endo pancreas. Similarly, please provide quantitative analysis of the number of cells of the various sub-lineages in the global versus conditional knockout.

2\) Please ensure that caveats related to the ChIP-seq datasets used (which are from insulinoma cell lines (MIN6)) are fully discussed. In particular, we would encourage inclusion of a discussion noting that insulinoma cell lines in vitro may have limited comparability to embryonic proto-endocrine cells. Similarly, discussion would be welcome of the limitations arising when population-derived datasets are compared, where the phenotype under consideration affects the precursors of some but not all sub-lineages in the population under study.

3\) Please review the manuscript for clarity. In particular, the reviewers have requested a more lucid presentation of what pathway Nkx2.2 is actually affecting -- i.e. to what extent is it required in endocrine progenitors for production of all endocrine lineages, rather than just for the β cell lineage as sometimes implied in the current text. Similarly, inclusion of more details of normal gene expression patterns in the relevant sections of text is encouraged, for instance, for Rfx6, Neurod1, etc., are these genes all expressed in proto-β-cells alone, or is there evidence for broader expression? We also request that the Abstract is rewritten for clarity.

4\) Please also attend to the following points:

a\) The paper suggests a role for Nkx2.2 in endocrine progenitors. However Ngn3+ progenitor cells are short lived before they give rise to hormone producing cells. Is it possible that by the time that Nkx2.2 protein is eliminated, the affected cells are already young β or α cells rather than Ngn3+ progenitors? This possibility does not detract from the importance of the story, but the distinction is important because of the fundamental difference between affecting fate of progenitors and directing terminal differentiation of β cells. Specifically, please indicate whether Nkx2.2-deficient, tomato+ cells that are Ngn3+ are present in the *Nkx2.2^Δendo^* mice. If not, it is hard to argue that the deletion affects progenitor cells and the text should be adjusted accordingly.

b\) The conclusions about cell fate and identity should be clarified, preferably also in the model ([Figure 5](#fig5){ref-type="fig"}). What happens to progenitor cells that lose Nkx2.2? The authors show that Ngn3 expression is reduced as in wild type, and that the cells do express general endocrine markers. What is less clear is whether lack of Nkx2.2 causes a shift in fate to alternative endocrine cell types like epsilon and pp, causes the formation of aberrant endocrine cells with mixed or no hormone expression, or does allow β cell specification (as reflected by expression of NeuroD1 for example) but not terminal differentiation. The transcriptome of the tomato+ cells could potentially be used to address this question, although caution is needed regarding the possibility raised in the point made above, that deletion in this model occurs after commitment to a β cell fate.

c\) The authors are encouraged to speculate about the role of Nkx2.2 in early pancreatic progenitors given the new findings -- e.g. could it have a key function at this stage that is masked by redundancy?

10.7554/eLife.20010.026

Author response

*Essential revisions:*

*1) Please include in [Figure 1](#fig1){ref-type="fig"} quantitative data showing that the area of tomato expression is equivalent in the control and Nkx2.2endo pancreas. Similarly, please provide quantitative analysis of the number of cells of the various sub-lineages in the global versus conditional knockout.*

We have added the quantitative data to [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. We counted the number of tomato labeled cells as a function of pancreas area. There is no difference between wild type and mutant. We have also provided the quantitative analysis of the numbers of sub-lineage islet cells in the *Nkx2.2^Δendo^* mice with the corresponding images presented in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. The cell number changes are consistent with the RNA changes. They are not as severe as the global KO, likely due to Cre efficiency -- which we discuss in the manuscript.

*2) Please ensure that caveats related to the ChIP-seq datasets used (which are from insulinoma cell lines (MIN6)) are fully discussed. In particular, we would encourage inclusion of a discussion noting that insulinoma cell lines* in vitro *may have limited comparability to embryonic proto-endocrine cells. Similarly, discussion would be welcome of the limitations arising when population-derived datasets are compared, where the phenotype under consideration affects the precursors of some but not all sub-lineages in the population under study.*

We have included discussion of these caveats. It is important to note that we compare all ChIP-seq data with in vivo expression data to ensure a gene is a bona fide target. We also agree that there are caveats associated with population-derived datasets and we have added this discussion to paragraph three of the Discussion section.

*3) Please review the manuscript for clarity. In particular, the reviewers have requested a more lucid presentation of what pathway Nkx2.2 is actually affecting -- i.e. to what extent is it required in endocrine progenitors for production of all endocrine lineages, rather than just for the β cell lineage as sometimes implied in the current text. Similarly, inclusion of more details of normal gene expression patterns in the relevant sections of text is encouraged, for instance, for Rfx6, Neurod1, etc., are these genes all expressed in proto-β-cells alone, or is there evidence for broader expression? We also request that the Abstract is rewritten for clarity.*

We had deliberately focused on the β cell lineage in our initial study, but we have now added the additional information about the other endocrine lineages. Much of the requested information was already provided in the Introduction, although we have added additional information about the pathways Nkx2.2 is affecting to the Introduction and Discussion. We have also rewritten the Abstract to improve clarity, but maintained the 150-word limit.

*4) Please also attend to the following points:a) The paper suggests a role for Nkx2.2 in endocrine progenitors. However Ngn3+ progenitor cells are short lived before they give rise to hormone producing cells. Is it possible that by the time that Nkx2.2 protein is eliminated, the affected cells are already young β or α cells rather than Ngn3+ progenitors? This possibility does not detract from the importance of the story, but the distinction is important because of the fundamental difference between affecting fate of progenitors and directing terminal differentiation of β cells. Specifically, please indicate whether Nkx2.2-deficient, tomato+ cells that are Ngn3+ are present in the Nkx2.2^Δendo^mice. If not, it is hard to argue that the deletion affects progenitor cells and the text should be adjusted accordingly.*

This is a valid point, but was also a difficult experiment since the Ngn3 and Nkx2.2 antibodies are both made in rabbit and the conditions we need to use for these antibodies quench the tomato signal. However, we have added a figure to [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} that shows low and high power images of adjacent sections of a pancreas from an e15.5 mouse. This data clearly shows that the majority of tomato-labeled positive cells are Nkx2.2-deficient and Ngn3 positive. We have added this statement to the text as well since it supports our interpretation and conclusions.

*b) The conclusions about cell fate and identity should be clarified, preferably also in the model ([Figure 5](#fig5){ref-type="fig"}). What happens to progenitor cells that lose Nkx2.2? The authors show that Ngn3 expression is reduced as in wild type, and that the cells do express general endocrine markers. What is less clear is whether lack of Nkx2.2 causes a shift in fate to alternative endocrine cell types like epsilon and pp, causes the formation of aberrant endocrine cells with mixed or no hormone expression, or does allow β cell specification (as reflected by expression of NeuroD1 for example) but not terminal differentiation. The transcriptome of the tomato+ cells could potentially be used to address this question, although caution is needed regarding the possibility raised in the point made above, that deletion in this model occurs after commitment to a β cell fate.*

The reviewers raise an important point that we have clarified in the text and in the model figure. We have shown previously using genetic lineage tracing that there is a shift in fate when Nkx2.2 is lost during pancreas development (using a null allele). We are unable to lineage label the β cells in the *Nkx2.2^Δendo^* mice since these mice already have Ngn3:Cre, which would confound any lineage labeling experiments with another Cre. However, we do not observe insulin producing cells expressing other hormones, suggesting we are not generating cells of mixed fate. We have clarified this point in the text. Furthermore, we have now determined in a separate study that deletion of Nkx2.2 in the β cells (after their commitment to the β cell fate) has a different phenotype than the *Nkx2.2^Δendo^* mice. This manuscript is now in press and we discuss these differences in this paper in the Discussion section.

*c) The authors are encouraged to speculate about the role of Nkx2.2 in early pancreatic progenitors given the new findings -- e.g. could it have a key function at this stage that is masked by redundancy?*

We have extended this discussion.
